Search results for "CLINICAL TRIALS"

showing 10 items of 490 documents

A precise stroke classification for evaluation of ischemic stroke subtypes and their relation with diabetes: is TOAST the best?

2010

To The Editor: Regarding the study by Turin et al1 performed to estimate the secular time trends in incidence using a population-based stroke registry in Japan, we discuss some issues of potential interest. First, have the authors classified stroke subtypes according TOAST classification or Oxfordshire classification? No mention has been made in the text concerning the classification methodology of ischemic stroke. It is conceivable that applying the TOAST classification2 of ischemic stroke (a classification with clinical, pathophysiological, anatomic, and instrumental basis that is easily applicable and widely validated) could provide a more precise selection of patients with lacunar strok…

TOAST ClassificationStroke registrymedicine.medical_specialtyLacunar strokePopulationMEDLINEBrain IschemiaPhysical medicine and rehabilitationRisk FactorsDiabetes mellitusMedicineHumanscardiovascular diseaseseducationStrokeAdvanced and Specialized Nursingeducation.field_of_studyClinical Trials as Topicbusiness.industrymedicine.diseaseStroke TOAST ClassificationStrokeIschemic strokePhysical therapyNeurology (clinical)Cardiology and Cardiovascular MedicinebusinessStroke
researchProduct

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

2020

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy caused by inhibitory autoantibodies against ADAMTS13 protein. Until recently, the combination of plasma exchange (PEX) and immunosuppression has been the standard front-line treatment in this disorder. However, aTTP-related mortality, refractoriness, and relapse are still a matter of concern. Areas covered: The better understanding of the pathophysiological mechanisms of aTTP has allowed substantial improvements in the diagnosis and treatment of this disease. Recently, the novel anti-VWF nanobody caplacizumab has been approved for acute episodes of aTTP. Caplacizumab is capable to block the adh…

Thrombotic microangiopathyExacerbationvirusesmedicine.medical_treatmentADAMTS13 ProteinDiseaseBioinformaticsAutoantigens03 medical and health sciencesPlatelet Adhesiveness0302 clinical medicineFibrinolytic AgentsProtein DomainsCrotalid Venomsvon Willebrand FactormedicineHumansImmunologic FactorsMulticenter Studies as TopicLectins C-TypeMolecular Targeted TherapyDrug ApprovalClinical Trials as TopicAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryStandard treatmentfungiImmunosuppressionDrugs InvestigationalHematologyAptamers NucleotideSingle-Domain Antibodiesbiochemical phenomena metabolism and nutritionmedicine.diseaseCombined Modality TherapyRecombinant ProteinsADAMTS13AcetylcysteineTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationCaplacizumabbusinessImmunosuppressive Agents030215 immunologyExpert Review of Hematology
researchProduct

A central nervous system-focused treatment approach for people with frozen shoulder: protocol for a randomized clinical trial

2019

Background: Frozen shoulder (FS) is a musculoskeletal condition of poorly understood etiology that results in shoulder pain and large mobility deficits. Despite some physical therapy interventions, such as joint mobilization and exercise, having shown therapeutic benefit, a definitive treatment does not currently exist. The aim of this study will be to compare the effectiveness of a central nervous system (CNS)-directed treatment program versus a standard medical and physical therapy care program on outcomes in participants with FS. Methods/design: The study is a two-group, randomized clinical trial with blinding of participants and assessors. Participants will be recruited via referrals fr…

Time FactorsJoint mobilizationDolor de hombro:Phenomena and Processes::Physical Phenomena::Time::Time Factors [Medical Subject Headings]Shoulder painShoulder adhesive capsulitisPsychological interventionMedicine (miscellaneous)law.invention:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Disability EvaluationStudy ProtocolDiscrimination Psychological0302 clinical medicineRandomized controlled trialFeedback Sensorylaw:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Physical Therapy Modalities [Medical Subject Headings]:Diseases::Musculoskeletal Diseases::Joint Diseases::Bursitis [Medical Subject Headings]Pharmacology (medical)030212 general & internal medicineRange of Motion ArticularPhysiotherapyFisioterapiaRandomized Controlled Trials as Topic:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Clinical Trials as Topic::Controlled Clinical Trials as Topic::Randomized Controlled Trials as Topic [Medical Subject Headings]lcsh:R5-920Shoulder JointFrozen shoulder:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Disability Evaluation [Medical Subject Headings]Treatment OutcomeCohortlcsh:Medicine (General):Anatomy::Musculoskeletal System::Skeleton::Joints::Shoulder Joint [Medical Subject Headings]medicine.medical_specialtyBlindingSensationContext (language use)03 medical and health sciencesBursitismedicineHumansPhysical Therapy Modalities:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings]:Geographical Locations::Geographic Locations::Europe::Spain [Medical Subject Headings]:Anatomy::Nervous System::Central Nervous System [Medical Subject Headings]business.industry:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Range of Motion Articular [Medical Subject Headings]Recovery of FunctionCapsulitismedicine.disease:Phenomena and Processes::Biological Phenomena::Recovery of Function [Medical Subject Headings]Sistema nervioso central:Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Nervous System Physiological Phenomena::Nervous System Physiological Processes::Sensation [Medical Subject Headings]SpainCentral nervous systemOrthopedic surgeryShoulder adhesivePhysical therapy:Phenomena and Processes::Physiological Phenomena::Physiological Processes::Homeostasis::Feedback Physiological::Feedback Sensory [Medical Subject Headings]business030217 neurology & neurosurgery
researchProduct

An overview of the clinical efficacy of mirtazapine

2002

Mirtazapine is at least as effective as the tricyclic antidepressants and trazodone in a wide range of patient subgroups including in- and out-patients with moderate to severe depression. It also appears to be at least as effective as the serotonin and noradrenaline reuptake inhibitor venlafaxine in the treatment of severely depressed melancholic patients. When compared with the selective serotonin reuptake inhibitors (SSRIs), mirtazapine shows a significantly earlier onset of action. Further analysis of a study comparing mirtazapine with the SSRI paroxetine indicated that early improvement was a highly sensitive predictor of later stable response for both drugs. The positive predictive val…

Time FactorsMirtazapineVenlafaxine HydrochlorideMirtazapineVenlafaxineMianserinAntidepressive Agents TricyclicPharmacologymedicineHumansPharmacology (medical)chemistry.chemical_classificationClinical Trials as TopicDepressive DisorderAdrenergic Uptake Inhibitorsbusiness.industryVenlafaxine HydrochlorideTrazodoneCyclohexanolsParoxetineAntidepressive AgentsParoxetinePsychiatry and Mental healthTreatment OutcomeNeurologychemistryNeurology (clinical)SerotoninOnset of actionbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTricyclicHuman Psychopharmacology: Clinical and Experimental
researchProduct

Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women

2014

AIM: To investigate the safety/efficacy of Boceprevirbased triple therapy in hepatitis C virus (HCV)-G1 menopausal women who were historic relapsers, partial-responders and null-responders. METHODS: In this single-assignment, unblinded study, we treated fifty-six menopausal women with HCV-G1, 46% F3-F4, and previous PEG-α/RBV failure (7% null, 41% non-responder, and 52% relapser) with 4 wk lead-in with PEG-IFNα2b/RBV followed by PEGIFNα2b/RBV+Boceprevir for 32 wk, with an additional 12 wk of PEG-IFN-α-2b/RBV if patients were HCV-RNA-positive by week 8. In previous null-responders, 44 wk of triple therapy was used. The primary objective of retreatment was to verify whether a sustained virolo…

Time FactorsViral HepatitisClinical Trials StudyHepacivirusViral hepatitiPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundPegylated interferonOdds RatioMultivariate AnalysiPegylated InterferonGastroenterologyGeneral MedicineHepatitis CHepatitis c virus treatmentMiddle AgedRecombinant ProteinViral LoadGenotype 1Recombinant ProteinsMenopauseTreatment OutcomeItalyRNA ViralDrug Therapy CombinationFemaleMenopauseViral hepatitisViral loadPegylated interferonHumanmedicine.drugmedicine.medical_specialtyGenotypeLogistic ModelProlineTime FactorInterferon alpha-2Hepatitis C virus treatmentAntiviral AgentsPharmacotherapyInternal medicineBoceprevirRibavirinmental disordersmedicineHumansAntiviral AgentHepacivirubusiness.industryInterferon-alphaBiomarkerGenotype 1; Hepatitis c virus treatment; Menopause; Pegylated interferon; Viral hepatitis; Antiviral Agents; Biomarkers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Logistic Models; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proline; RNA Viral; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Menopause; GastroenterologyHepatitis C Chronicmedicine.diseaseVirologyLogistic ModelschemistryHepatitis C Virus PositiveMultivariate AnalysisGenotype 1; Hepatitis C virus treatment; Menopause; Pegylated Interferon; Viral HepatitisbusinessBiomarkers
researchProduct

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra: immunogenicity and safety profile

2009

Abstract Priorix-Tetra ™ (GlaxoSmithKline Biologicals) is a combined measles, mumps, rubella and varicella (MMRV) vaccine. Eight studies involving more than 3000 children were reviewed. Compared with co-administration of MMR ( Priorix ™) and varicella ( Varilrix ™) vaccines, the MMRV vaccine showed: similar immunogenicity, with immunity shown up to 3 years post-vaccination; a higher rate of fever after the first dose; a slight increase in mild local reactions after the second dose. This MMRV vaccine can be used either as a two-dose vaccine or as a second dose in children primed with separate MMR and/or varicella vaccines, offering a convenient way to introduce varicella vaccination into rou…

Varicella vaccineImmunization Secondarymedicine.vaccineAntibodies ViralRubellaMeaslesChickenpox VaccinemedicineHumansVaccines CombinedChildClinical Trials as TopicReactogenicityMMRV vaccineGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational HealthInfantvirus diseasesmedicine.diseaseVirologyVaccinationInfectious DiseasesImmunizationChild PreschoolMolecular MedicinebusinessMeasles-Mumps-Rubella Vaccine
researchProduct

From the oxygen to the organ protection: Erythropoietin as protagonist in internal medicine

2006

Erythropoietin (EPO), already known as the stimulating hormone for erythropoiesis, has shown different and interesting pleiotropic actions. It does not only affect erythroid cells, but also myeloid cells, lymphocytes and megakaryocytes. This hormone can also enhance phagocytic function of the polymorphonuclear cells and reduce the activation of macrophages, thus modulating the inflammatory process.Moreover, hematopoietic and endothelial cells probably have the same cellular origin, and the discovery of erythropoietin receptors (EPO-R) also on mesangial and myocardial cells, smooth muscle fibrocells and neurons has prompted the study of the non-erythropoietic functions of this hormone.The in…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyIschemiaNeovascularizationIschemiahemic and lymphatic diseasesInternal medicinemedicineErythropoietin (EPO); pleiotropic actions; erythropoietin receptors (EPO-R); VEGFHumansOxygen tensionReceptorHypoxiaErythropoietinPharmacologyClinical Trials as Topicbusiness.industryPleiotropic actionerythropoietin receptors (EPO-R)pleiotropic actionsAngiogenesis Modulating AgentsApoptosiAnemiaShockHematologymedicine.diseaseVEGFHaematopoiesisAngiogenesiEndocrinologyApoptosisErythropoietinErythropoietin (EPO)Erythropoiesismedicine.symptombusinessCardiology and Cardiovascular MedicineHormonemedicine.drugReceptor
researchProduct

Efficacy and tolerability of a fixed dose combination of cortex phospholipid liposomes and cyanocobalamin for intramuscular use in peripheral neuropa…

2019

Peripheral neuropathies are frequently encourtered in clinical practice and are assiociated with a major impairment in quality of life . Howewvwr, their management reamans poor, and current therapies are often burdened with major side effects and can present poor efficacy on pain and functionality. Therefore, it has been suggested that the combination of two or more different drugs may improve analgesis efficacy and reduce side effects. Tricortin 1000 is formulated with 12 mg of Brain cortex phospholipid liposomes + 1000 microgrammi of Cyanocobalamin injectable (PL+ CNCb1) for intramuscolar use and is indicated in the tratment of poly-algo-neuropathic syndromes. This combination exerts a ma…

Viitamin B 12Fixed-dose combinationAnalgesicPharmacologyInjections IntramuscularInjections03 medical and health sciences0302 clinical medicinePharmacotherapyPeripheral nervous system diseasemedicineHumansCyanocobalaminphospholipidPhospholipidsCerebral CortexIntramuscularAnalgesicsClinical Trials as TopicNeck painLiposomebiologybusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaBack painPeripheral Nervous System DiseasesGeneral MedicineBack pain; Liposomes; Neuralgia; Peripheral nervous system diseases; Phospholipids; Vitamin B 12; Analgesics; Cerebral Cortex; Clinical Trials as Topic; Drug Combinations; Humans; Injections Intramuscular; Liposomes; Neuroprotective Agents; Peripheral Nervous System Diseases; Phospholipids; Vitamin B 12Drug CombinationsVitamin B 12Neuroprotective AgentsTolerability030220 oncology & carcinogenesisLiposomesbiology.proteinNeuralgia030211 gastroenterology & hepatologyIiposomemedicine.symptombusinessNeurotrophinMinerva Medica
researchProduct

Clinical effect of vitamin C supplementation on bone healing: A systematic review

2022

Background: The aim of the present systematic review was to evaluate the clinical effect of vitamin C on bone healing after bone fracture or bone reconstruction procedures. Material and Methods: In October 2020, Cochrane Library, Scopus and PubMed-Medline databases were searched without restrictions to identify animal and human studies that fulfilled the eligibility criteria. Outcome measures were bone healing time, bone gain (mm), bone density and adverse events. The risk of bias assessment of the selected studies was evaluated by means of Cochrane Collaboration's Tool for randomized clinical trials, while randomized clinical animal trials were assessed according to SYRCLE's tool. Addition…

Vitamina CBonescamSuplements nutritiusAscorbic AcidVitaminsDietary supplementsmucormycosisBone and BonesgingivaClinical trialsOtorhinolaryngologycovid-19giant cellsBone DensityDietary SupplementsOssosAnimalsHumansSurgeryVitamin CGeneral DentistryUNESCO:CIENCIAS MÉDICASAssaigs clínics
researchProduct

Efficacy and safety assessment of azithromycin 1.5% eye drops (azyter) in peri-operative antibio-prophylaxis for cataract surgery

2009

International audience; Introduction: Background: Endophthalmitis is still one of the most fearsome complications of cataract surgery. The most important pathogens causing post-operative phacoemulsification endophthalmitis are staphylococci. Methods: 85 patients were included in a phase II pilot study. Patients were divided in three groups, group 1 and 3 received either azithromycin 1.5% eye drops or placebo eye drops one day before surgery and for 2 days after surgery and group 2 received azithromycin 1.5% eye drops for 3 days after surgery. Treatments were administered twice a day: one drop in the morning and one in the evening. Bacterial samples were collected three times from the conjun…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organscataractclinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organsantibiotics/antifungals/antiparasitics[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct